Pfizer PFE Biopharma — Other Nonoperating Income (Expense)

Similar metrics at other companies

YUMUnallocated — Other Nonoperating Income (Expense)

$45M+650%

TGTReportable Segment — Other Nonoperating Income (Expense)

$15M-42.3%

YUMTotal Division — Other Nonoperating Income (Expense)

$0+100%

CVNAReportable Segment — Other Nonoperating Income (Expense)

$0+100%

YUMKFC Global Division — Other Nonoperating Income (Expense)

$0—

YUMPizza Hut Global Division — Other Nonoperating Income (Expense)

-$3M-50.0%

FAQ

What is Pfizer's biopharma — other nonoperating income (expense)?

Pfizer (PFE) reported biopharma — other nonoperating income (expense) of $116M in Q1 2026.

How has Pfizer's biopharma — other nonoperating income (expense) changed year-over-year?

Pfizer's biopharma — other nonoperating income (expense) increased by 48.7% year-over-year, from $78M to $116M.

What is the long-term trend for Pfizer's biopharma — other nonoperating income (expense)?

Over 3 years (2022 to 2025), Pfizer's biopharma — other nonoperating income (expense) has grown at a -5.3% compound annual growth rate (CAGR), from $685M to $581M.

What does biopharma — other nonoperating income (expense) mean?

This metric captures the net financial impact of activities outside the core pharmaceutical research, development, and commercialization operations for the Biopharma segment. It typically includes items such as interest income, interest expense, gains or losses from equity investments, and other miscellaneous financial adjustments that are not directly tied to the primary drug manufacturing and sales business. By isolating these non-core items, investors can better assess the underlying operational performance of the pharmaceutical business.